ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03201965
Recruitment Status : Recruiting
First Posted : June 28, 2017
Last Update Posted : October 19, 2018
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

Condition or disease Intervention/treatment Phase
Amyloidosis Drug: Cyclophosphamide Drug: Bortezomib Drug: Dexamethasone, 40 mg Drug: Daratumumab Phase 3

Detailed Description:
Participant involved in study for approx. 8 years duration includes Screening Phase (complete clinical evaluation will be done), Treatment Phase (monitoring of adverse events (AEs), laboratory abnormalities and clinical response), Post-Treatment Observation Phase (disease evaluations will be done) and a Long-term Follow-up Phase (Subsequent anticancer treatment, response to subsequent treatment, date of progression and survival status will be obtained every 16 weeks).The primary hypothesis is that daratumumab in combination with CyBorD will improve the overall complete hematological response rate compared to CyBorD alone in AL amyloidosis participants. Safety will be assessed by AEs, laboratory test results, electrocardiogram, vital sign measurements, physical examination, and Eastern Cooperative Oncology Group (ECOG) performance status.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 370 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
Actual Study Start Date : October 5, 2017
Estimated Primary Completion Date : January 22, 2021
Estimated Study Completion Date : October 30, 2025


Arm Intervention/treatment
Active Comparator: CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)
Participants will receive dexamethasone (40 milligrams [mg] orally or intravenous [IV] dose), followed by cyclophosphamide (300 milligram per meter square [mg/m^2] orally or IV dose), then bortezomib (1.3 mg/m^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
Drug: Cyclophosphamide
Participants will receive 300 mg/m^2 of cyclophosphamide as an oral or IV dose.

Drug: Bortezomib
Participants will receive 1.3 mg/m^2 of bortezomib as an subcutaneous (SC) injection.

Drug: Dexamethasone, 40 mg
Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.

Experimental: CyBorD plus Daratumumab
Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m^2 orally or IV dose weekly) and bortezomib (1.3 mg/m^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
Drug: Cyclophosphamide
Participants will receive 300 mg/m^2 of cyclophosphamide as an oral or IV dose.

Drug: Bortezomib
Participants will receive 1.3 mg/m^2 of bortezomib as an subcutaneous (SC) injection.

Drug: Dexamethasone, 40 mg
Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.

Drug: Daratumumab
Participants will receive 1800 mg of daratumumab subcutaneously.




Primary Outcome Measures :
  1. Percentage of Participants With Overall Complete Hematologic Response [ Time Frame: Approximately 3 years ]
    Overall complete hematologic response rate will be defined as percentage of participants who achieve Complete Hematologic Response (CHR), according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum and urine immunofixation.


Secondary Outcome Measures :
  1. Major Organ Deterioration Progression-Free Survival (MOD-PFS) [ Time Frame: Approximately 5 years ]
    MOD-PFS is defined from randomization to any one of following events, whichever comes first: death; clinical manifestation of cardiac/renal failure; development of hematologic progression of disease. Clinical manifestation of cardiac failure: development of dyspnea at rest (for at least 3 consecutive days) and due solely to amyloidosis cardiac deterioration, or need for cardiac transplant, left ventricular assist device, or intraaortic balloon pump or clinical manifestation of renal failure: development of end-stage renal disease (need for hemodialysis or renal transplant). Hematologic progression of disease: from CHR, abnormal free light chain ratio (light chain must be double), or from CHR/ VGPR (very good partial response) /PR (partial response), 50 percent (%) increase in serum M-protein to greater than (>) 0.5 gram per deciliter (g/dL) or 50% increase in urine M-protein to >200 milligram per day (mg/day); free light chain increase of 50% to > 100 mg/L.

  2. Progression-Free Survival (PFS) [ Time Frame: Approximately 5 years ]
    Progression-free survival (PFS) is defined as time from date of randomization to date of first documentation of hematologic disease progression, or organ (cardiac, renal, or liver) progression, or death due to any cause, whichever occurs first. Hematologic disease progression: from CHR, any detectable monoclonal protein or abnormal free light chain ratio (light chain must be double), from PR, 50% increase in serum M-protein to > 0.5 g/dL or 50% increase in urine M-protein to > 200 mg/day; free light chain increase of 50% to > 100 mg/L. Organ progression for heart: NT-proBNP progression [> 30%; > 300 ng/l increase] or cardiac troponin (cTn) progression [greater than or equal to (>=) 33% increase] or ejection fraction progression [>= 10% decrease]; for kidney: renal progression is defined as a >=25% estimated glomerular filtration rate (eGFR) decrease.

  3. Organ Response Rate (OrRR) [ Time Frame: Approximately 5 years ]
    Organ response rate (OrRR) for kidney, heart, liver is defined as the proportion of baseline organ involved participants who achieve organ response in each corresponding organ. Organ response defined for heart :N-terminal brain pronatriuretic peptide (NT-proBNP) response (> 30% and > 300 nanogram per liter [ng/L] decrease in participants with baseline NT-proBNP >= 650 ng/L) or New York Heart Association (NYHA) class response (>= 2 class decrease in participants with baseline NYHA class 3 or 4); for kidney: decrease in proteinuria by >=30% or below 0.5 grams /24 hours without renal progression; for liver: 50% decrease in abnormal alkaline phosphatase value.

  4. Overall Survival (OS) [ Time Frame: Approximately 8 years ]
    Overall survival (OS) is measured from the date of randomization to the date of the participant's death.

  5. Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Fatigue Scale Score [ Time Frame: Baseline, up to end of study (approximately 5 years) ]
    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

  6. Change From Baseline in the 36-Item Short Form Survey version 2 (SF-36v2) Mental Component Summary (MCS) [ Time Frame: Baseline, up to end of study (approximately 5 years) ]
    The 36-Item Short Form Survey version 2 (SF-36v2) is a survey of participant health. It consists of 8 individual domains, which are weighted sums of the questions in their section. The 8 domains are: vitality (VT), physical functioning (PF), bodily pain (BP), general health (GH), Role-Physical (RP), Role-Emotional (RE), social functioning (SF) and mental health (MH). Each of these 8 scales (domains) is scored from 0 to 100 with higher scores indicating better health. Based on the scale scores, the summary mental component score (MCS) is derived. Scales contributing most to the scoring of the SF-36 MCS include the VT, SF, RE and MH. Other domains not noted contribute to the scoring but to a lesser degree. The scoring is derived based on an algorithm that has been developed in a software provided by the developer. The summary MCS score is also scaled from 0 to 100 with higher scores indicating better health.

  7. Change From Baseline in the EORTC QLQ-C30 Global Health Status Scale Score [ Time Frame: Baseline, up to end of study (approximately 5 years) ]
    The European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ)-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.

  8. Time to Next Treatment (TNT) [ Time Frame: Approximately 5 years ]
    Time to next treatment (TNT) defined as the time from the date of randomization to the start date of subsequent treatment for AL amyloidosis treatment.

  9. Hematologic Very Good Partial Response or Better Rate [ Time Frame: Approximately 3 years ]
    Hematologic very good partial response or better rate is defined as the percentage of participants who achieve hematologic complete response or very good partial response. Complete response: normalization of free light chain levels and ratio, negative serum and urine immunofixation; Very good partial response: reduction in the dFLC less than 40 mg/L.

  10. Time to Complete Hematologic Response [ Time Frame: Approximately 3 years ]
    Time to complete hematologic response is defined as the time between the date of randomization and the first efficacy evaluation at which the participant has met the criteria for hematologic complete response.

  11. Time to Hematologic Very Good Partial Response (VGPR) or Better Response [ Time Frame: Approximately 3 years ]
    Time to hematologic VGPR or better response is defined as the time between the date of randomization and the first efficacy evaluation at which the participant has met the criteria for hematologic VGPR or better response.

  12. Duration of Complete Hematologic Response [ Time Frame: Approximately 5 years ]
    Duration of complete hematologic response is defined as the time between the date of initial documentation of complete hematologic response to the date of first documented evidence of hematologic progressive disease.

  13. Duration of Hematologic Very Good Partial Response (VGPR) or Better Response [ Time Frame: Approximately 5 years ]
    Duration of hematologic VGPR or better response is defined as the time between the date of initial documentation of hematologic VGPR or better response to the date of first documented evidence of hematologic progressive disease.

  14. Time to Organ Response [ Time Frame: Approximately 5 years ]
    Time to organ response is defined as the time between the date of randomization and the first efficacy evaluation at which the participant has each corresponding organ response.

  15. Duration of Organ Response [ Time Frame: Approximately 5 years ]
    Duration of organ response is defined as the time between the date of initial documentation of each corresponding organ response to the date of first documented evidence of the corresponding organ progressive disease.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histopathological diagnosis of amyloidosis based on detection by immunohistochemistry and polarizing light microscopy of green bi-refringent material in congo red stained tissue specimens (in an organ other than bone marrow) or characteristic electron microscopy appearance
  • Measurable disease of amyloid light-chain (AL) amyloidosis as defined by at least one of the following:

    1. serum monoclonal (M)-protein greater than or equal (>=) 0.5 grams/deciliter (g/dL) by protein electrophoresis (routine serum protein electrophoresis and immunofixation [IFE] performed at a central laboratory)
    2. serum free light chain greater than or equal to (>=) 5.0 milligram/deciliter (mg/dL) with an abnormal kappa:lambda ratio or the difference between involved and uninvolved free light chains (dFLC) >= 5 mg/ dL
  • One or more organs impacted by AL amyloidosis according to consensus guidelines
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2

Exclusion Criteria:

  • Prior therapy for AL amyloidosis or multiple myeloma including medications that target CD38, with the exception of 160 mg dexamethasone (or equivalent corticosteroid) maximum exposure prior to randomization
  • Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, >= 60 percent (%) plasma cells in the bone marrow, or hypercalcemia
  • Evidence of significant cardiovascular conditions as specified below:

    1. NT-ProBNP > 8500 nanogram per liter (ng/L)
    2. New York Heart Association (NYHA) classification IIIB or IV heart failure
    3. Heart failure that in the opinion of the investigator is on the basis of ischemic heart disease (eg, prior myocardial infarction with documented history of cardiac enzyme elevation and electrocardiogram [ECG] changes) or uncorrected valvular disease and not primarily due to AL amyloid cardiomyopathy
    4. Inpatient admission to a hospital for unstable angina or myocardial infarction within the last 6 months prior to first dose or percutaneous cardiac intervention with recent stent within 6 months or coronary artery bypass grafting within 6 months
    5. For participants with congestive heart failure, cardiovascular-related hospitalizations within 4 weeks prior to randomization
    6. Participants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular (AV) nodal or sinoatrial (SA) nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillators [ICD] is indicated but not placed (participants who do have a pacemaker/ICD are allowed on study)
    7. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) > 500 milliseconds (msec). Participants who have a pacemaker may be included regardless of calculated QTc interval
    8. Supine systolic blood pressure < 90 millimeter of mercury (mmHg), or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of > 20 mmHg despite medical management (eg, midodrine, fludrocortisones) in the absence of volume depletion
  • Planned stem cell transplant during the first 6 cycles of protocol therapy are excluded. Stem cell collection during the first 6 cycles of protocol therapy is permitted
  • Know to be seropositive for human immunodeficiency virus (HIV)
  • Any one of the following:

    1. Known to be seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Participants with resolved infection (ie, participants who are positive for antibodies to hepatitis B core antigen [antiHBc] and/or antibodies to hepatitis B surface antigen [antiHBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded
    2. Known to be seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)
  • Grade 2 sensory or Grade 1 painful peripheral neuropathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03201965


Contacts
Contact: Study Contact 844-434-4210 JNJ.CT@sylogent.com

  Hide Study Locations
Locations
United States, Arizona
Mayo Clinic Arizona Not yet recruiting
Phoenix, Arizona, United States, 85054
United States, California
City of Hope Recruiting
Duarte, California, United States, 91010
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Stanford University Recruiting
Stanford, California, United States, 94305
United States, Colorado
University of Colorado Recruiting
Aurora, Colorado, United States, 80045
Colorado Blood Cancer Institute Recruiting
Denver, Colorado, United States, 80218
United States, Florida
Mayo Clinic Not yet recruiting
Jacksonville, Florida, United States, 32224
United States, Georgia
Winship Cancer Institute Emory University Recruiting
Atlanta, Georgia, United States, 30322
United States, Maryland
University of Maryland Not yet recruiting
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Boston University Medical Center Recruiting
Boston, Massachusetts, United States, 02118
Dana-Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02215-5418
United States, Michigan
Barbara Ann Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
United States, Minnesota
Mayo Clinic Rochester Not yet recruiting
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
United States, New York
Memorial Sloan Kettering Not yet recruiting
New York, New York, United States, 10021
Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects Withdrawn
New York, New York, United States, 10029
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Weill Cornell Medical College Recruiting
New York, New York, United States, 10065
University of Rochester Medical Center Recruiting
Rochester, New York, United States, 14642
United States, North Carolina
Levine Cancer Institute Recruiting
Charlotte, North Carolina, United States, 28204
Wake Forest University Health Sciences - Cardiovascular Medicine Recruiting
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
The Ohio State University Recruiting
Columbus, Ohio, United States, 43210
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
United States, Pennsylvania
Penn State Hershey Medical Center Withdrawn
Hershey, Pennsylvania, United States, 17033
University of Pennsylvania Medical Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
United States, Texas
University of Texas, MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute Recruiting
Salt Lake City, Utah, United States, 84112
United States, Washington
Swedish Cancer Institute Withdrawn
Seattle, Washington, United States, 98104
Seattle Cancer Care Alliance Recruiting
Seattle, Washington, United States, 98109
Australia
Box Hill Hospital Recruiting
Box Hill, Australia, 3128
Sir Charles Gairdner Hospital Recruiting
Nedlands, Australia, 6009
Westmead Hospital Recruiting
Westmead, Australia, 2145
Princess Alexandra Hospital Recruiting
Woolloongabba, Australia, 4102
Belgium
Institut Jules Bordet Recruiting
Brussel, Belgium, 1000
UZ Gent Recruiting
Gent, Belgium, 9000
Az Groeninge Recruiting
Kortrijk, Belgium, 8500
Universitair Ziekenhuis Leuven Recruiting
Leuven, Belgium, 3000
Brazil
Hospital de Clínicas de Porto Alegre Recruiting
Porto Alegre, Brazil, 90035-903
Sociedade Pernambucana de Combate ao Cancer Recruiting
Recife, Brazil, 50040-000
Instituto D'Or de Pesquisa e Ensino (IDOR) Withdrawn
Rio De Janeiro, Brazil, 22271-110
Instituto COI de Pesquisa, Educação e Gestão Recruiting
Rio De Janeiro, Brazil, 22793-080
CEHON Recruiting
Salvador, Brazil, 45995-000
Hospital de Base de São José do Rio Preto Recruiting
São José Do Rio Preto, Brazil, 15090-000
Clinica Sao Germano Recruiting
São Paulo, Brazil, 01455-010
IAMSPE Not yet recruiting
São Paulo, Brazil, 04039-004
HCFMUSP Recruiting
São Paulo, Brazil, 05403-010
Instituto Israelita de Ensino e Pesquisa Albert Einstein - Centro de Pesquisa Clinica Withdrawn
São Paulo, Brazil, 05652-000
Canada, Alberta
Alberta Health Services Recruiting
Calgary, Alberta, Canada, T2N 4N2
Alberta Health Services Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Vancouver General Hospital Recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, Ontario
London Health Sciences Center Recruiting
London, Ontario, Canada, N6A 5W9
University Health Network (UHN) Princess Margaret Cancer Centre Not yet recruiting
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
McGill University Health Centre Recruiting
Montreal, Quebec, Canada, H4A 3J1
China
Beijing Chaoyang Hospital Not yet recruiting
Beijing, China, 100020
Peking University People's Hospital Not yet recruiting
Beijing, China, 100044
First affiliated Hospital of Zhejiang University Not yet recruiting
Hangzhou, China, 310020
Nanjing General Hospital Not yet recruiting
Nanjing, China, 210002
Ruijin Hospital, Shanghai Jiao Tong University Not yet recruiting
Shanghai, China, 200025
Denmark
Aarhus University Hospital Not yet recruiting
Aarhus C, Denmark, 8000
Dep. of Hematology, Rigshospitalet Not yet recruiting
Copenhagen, Denmark, 2400
Odense Universitets Hospital Not yet recruiting
Odense, Denmark
France
CHU Dijon Not yet recruiting
Dijon, France, 21000
Hopital Claude Huriez Recruiting
Lille Cedex, France, 59037
CHU de Limoges - Fédération Hépatologie Recruiting
Limoges, France, 87000
Institut Paoli Calmettes Recruiting
Marseille, France, 13273
Chu Hotel Dieu Recruiting
Nantes Cedex 01, France, 44035
Hopital Saint-Louis Recruiting
Paris Cedex 10, France, 75475
Centre hospitalier Lyon-Sud Recruiting
Pierre - Bénite Cedex, France, 69495
CHU De Poitiers Recruiting
Poitiers, France, 86000
CHU Rangueil Recruiting
Toulouse, France, 31400
CHU Bretonneau Recruiting
Tours Cedex, France, 37044
CHU de Nancy_ Hôpital Brabois Recruiting
Vandoeuvre Les Nancy, France, 54511
Germany
Charite Campus Benjamin Franklin Not yet recruiting
Berlin, Germany, 12203
Heinrich-Heine-Universität Düsseldorf Not yet recruiting
Düsseldorf, Germany, 40225
Universitatsklinikum Essen Not yet recruiting
Essen, Germany, 45122
HOPA-Hämatologisch-Onkologische Praxis Altona MVZ GmbH Recruiting
Hamburg, Germany, 22767
Universitaetsklinikum Heidelberg Medizinische Klinik V Recruiting
Heidelberg, Germany, 69120
Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Not yet recruiting
Tübingen, Germany, 72076
Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii Not yet recruiting
Würzburg, Germany, 97080
Greece
Alexandra General Hospital of Athens Recruiting
Athens, Greece, 11528
University General Hospital of Rio Recruiting
Patra, Greece, 26500
Hungary
Semmelweis Egyetem I.Belgyogyaszati Klinika Recruiting
Budapest, Hungary, 1083
Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Szent László Te Recruiting
Budapest, Hungary, 1097
Semmelweis Egyetem Recruiting
Budapest, Hungary
Israel
Carmel Hospital Recruiting
Haifa, Israel, 34362
Hadassah Medical Center Recruiting
Jerusalem, Israel, 91120
Sheba Medical Center Recruiting
Ramat-Gan, Israel, 52621
Sourasky Medical Center Recruiting
Tel-Aviv, Israel, 6423906
Assaf Ha'Rofeh Medical Center Recruiting
Zerifin, Israel, 70300
Italy
Policlinico di Bari Not yet recruiting
Bari, Italy, 70124
Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi Recruiting
Bologna, Italy, 40138
Casa di Cura La Maddalena Recruiting
Palermo, Italy, 90146
Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo Recruiting
Pavia, Italy, 27100
Dipartimento Di Biotecnologie Cellulari Ed Ematologia-Università "La Sapienza",Policlinico Umberto I Recruiting
Roma, Italy, 00161
A.O.U. Città della Salute e della Scienza Recruiting
Torino, Italy, 10126
Japan
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Recruiting
Hiroshima, Japan, 730-8619
Kanazawa University Hospital Recruiting
Kanazawa, Japan, 920-8641
Kumamoto University Hospital Not yet recruiting
Kumamoto-City, Japan, 860-8556
Kyoto Kuraguchi Medical Center Recruiting
Kyoto, Japan, 603-8151
Shinshu University Hospital Recruiting
Matsumoto, Japan, 390-8621
Matsuyama Red Cross Hospital Recruiting
Matsuyama, Japan, 790-8524
Nagoya City University Hospital Recruiting
Nagoya, Japan, 467-8602
National Hospital Organization Okayama Medical Center Not yet recruiting
Okayama, Japan
Japanese Red Cross Central Medical Center Recruiting
Shibuya, Japan, 150-8935
Tokushima University Hospital Not yet recruiting
Tokushima, Japan, 770-8503
Korea, Republic of
Pusan National University Hospital. Recruiting
Busan, Korea, Republic of, 49241
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 03080
Severance Hospital, Yonsei University Health System Recruiting
Seoul, Korea, Republic of, 03722
Asan Medical Center Not yet recruiting
Seoul, Korea, Republic of, 05505
Samsung Medical Center Recruiting
Seoul, Korea, Republic of, 06351
The Catholic University of Korea Seoul St. Mary's Hospital Recruiting
Seoul, Korea, Republic of, 06591
Mexico
Centro de Investigación Farmacéutica Especializada Recruiting
Guadalajara, Mexico, 44160
Centro Medico Nacional La Raza, IMSS Not yet recruiting
Mexico City, Mexico, 02990
Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán Withdrawn
Mexico City, Mexico, 14080
Hospital Universitario 'Dr. Jose Eleuterio Gonzalez' Recruiting
Monterrey, Mexico, 64460
Netherlands
Haga ziekenhuis Recruiting
Den Haag, Netherlands, 2545 AA
UMCG Not yet recruiting
Groningen, Netherlands, 9713 GZ
Erasmus MC Recruiting
Rotterdam, Netherlands, 3015 CN
UMC Utrecht Recruiting
Utrecht, Netherlands, 3584 CX
Maxima Medisch Centrum Recruiting
Veldhoven, Netherlands, 5504 DB
Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich Not yet recruiting
Chorzów, Poland, 41-500
SKPP UM w Poznaniu Not yet recruiting
Poznan, Poland, 60-569
Instytut Hematologii i Transfuzjologii Not yet recruiting
Warszawa, Poland, 02-776
Romania
Institut Clinic Fundeni Not yet recruiting
Bucuresti, Romania, 22328
Institutul Regional de Oncologie Iasi Not yet recruiting
Iasi, Romania, 700483
Spain
Hosp. Univ. Germans Trias I Pujol Recruiting
Badalona, Spain, 08916
Hosp. Univ. Vall D Hebron Recruiting
Barcelona, Spain, 08035
Hosp. Clinic I Provincial de Barcelona Recruiting
Barcelona, Spain, 08036
Hosp. Univ. Ramon Y Cajal Recruiting
Madrid, Spain, 28034
Hosp. Univ. Fund. Jimenez Diaz Recruiting
Madrid, Spain, 28040
Hosp. Univ. 12 de Octubre Recruiting
Madrid, Spain, 28041
Clinica Univ. de Navarra Recruiting
Pamplona, Spain, 31008
Hosp. Clinico Univ. de Salamanca Recruiting
Salamanca, Spain, 37007
Hosp. Univ. de Canarias Recruiting
San Cristóbal De La Laguna, Spain, 38320
Hosp. Univ. Dr. Peset Recruiting
Valencia, Spain, 46017
Sweden
South Elvsborg Hospital Not yet recruiting
Boras, Sweden, 501 82
Skanes universitetssjukhus Not yet recruiting
Lund, Sweden, 221 85
Karolinska University Hospital, Huddinge Withdrawn
Stockholm, Sweden, 141 86
Akademiska Sjukhuset Withdrawn
Uppsala, Sweden, 751 85
Turkey
Ankara Universitesi Tip Fakultesi Cebeci Hastanesi Recruiting
Ankara, Turkey, 06590
Akdeniz University Medical Faculty Recruiting
Antalya, Turkey, 7059
Ondokuz Mayis Universitesi Tip Fakultesi Recruiting
Atakum, Turkey, 55270
Trakya University Medical Faculty Not yet recruiting
Edirne, Turkey, 22030
Istanbul University Istanbul Medical Faculty Recruiting
Istanbul, Turkey, 34093
Istanbul University Cerrahpasa Medical Faculty Not yet recruiting
Istanbul, Turkey, 34096
Dokuz Eylul Universitesi Tip Fakultesi Recruiting
Izmir, Turkey, 35340
Erciyes University Medical Faculty Recruiting
Talas, Turkey, 38039
United Kingdom
University Hospitals Birmingham NHS Trust, Not yet recruiting
Birmingham, United Kingdom, B15 2TH
University College Hospital Not yet recruiting
London, United Kingdom, NW1 2PG
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC

Additional Information:
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT03201965     History of Changes
Other Study ID Numbers: CR108193
2016-001737-27 ( EudraCT Number )
54767414AMY3001 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: June 28, 2017    Key Record Dates
Last Update Posted: October 19, 2018
Last Verified: October 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Amyloidosis
Proteostasis Deficiencies
Metabolic Diseases
Dexamethasone acetate
Dexamethasone
Daratumumab
Cyclophosphamide
Bortezomib
BB 1101
Antibodies, Monoclonal
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists